MIRA
INFORM REPORT
|
Report Date : |
25.01.2007 |
IDENTIFICATION
DETAILS
|
Name : |
GREEN
SIGNAL BIO PHARMA PRIVATE LIMITED |
|
|
|
|
Registered Office : |
Old
No.5, New No.13/A3, Sai Niketan Circular Road, United India Colony,
Kodambakkam, Chennai-600024, Tamilnadu |
|
|
|
|
Country : |
India |
|
|
|
|
Date of Incorporation : |
21.11.2005 |
|
|
|
|
Com. Reg. No.: |
18-58068 |
|
|
|
|
CIN No.: [Company
Identification No.] |
U24232TN2005PTC058068 |
|
|
|
|
TAN No.: [Tax
Deduction & Collection Account No.] |
CHEG07968C |
|
|
|
|
PAN No.: [Permanent
Account No.] |
AACCG4791M |
|
|
|
|
Legal Form : |
A
Private Limited LiabilityCompany |
|
|
|
|
Line of Business : |
Manufacturers
of Vaccine |
RATING & COMMENTS
|
MIRA’s Rating : |
C |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
<10 |
C |
Absolute credit risk exists. Caution
needed to be exercised |
Credit not recommended |
|
Maximum Credit Limit : |
|
|
|
|
|
Status : |
New
Company |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
In
absence of required financial and business details, it would be prudent to
deal with the company on safe and secured trade terms and conditions,
initially. |
LOCATIONS
|
Registered Office : |
Old
No.5, New No.13/A3, Sai Niketan Circular Road, United India Colony,
Kodambakkam, Chennai-600024, Tamilnadu, India |
|
Tel. No.: |
91-44-24729799/
24839966 |
|
Mobile No.: |
91-9444118383/
9444118484 |
|
Fax No.: |
91-44-24721962 |
|
E-Mail : |
|
|
Website : |
DIRECTORS
|
Name : |
Mr. P.
Sundaraparipooranam |
|
Designation : |
Chairman |
|
Address : |
Old
No.5, New No.13/A3, Sai Niketan Circular Road, United India Colony,
Kodambakkam, Chennai-600024, Tamilnadu, India |
|
Date of Birth/Age : |
24.05.1970 |
|
Date of Appointment : |
22.06.2006 |
|
Other Directorships : |
Vatsan
Bio Pharma Private Limited |
|
|
|
|
Name : |
Mrs.
Saradha Ramakrishana |
|
Designation : |
Director |
|
Address : |
23/3B,
III Main road, United India Colony, Kodambakkam, Chennai-600024, Tamilnadu,
India |
|
Date of Birth/Age : |
23.04.1960 |
|
Date of Appointment : |
22.06.2006 |
|
|
|
|
Name : |
Mr. B.
Dakshayani |
|
Designation : |
Director |
|
Address : |
6/14,
Munuswamy Street, Sarathy Nagar, Saidapet, Chennai-600015, Chennai,
Tamilnadu, India |
|
Date of Appointment : |
22.11.2005 |
MAJOR SHAREHOLDERS
|
Names
of Shareholders |
No. of Shares |
|
Mr. P.
Sundaraparipooranan |
9900 |
|
Mr. B.
Dhakshayani |
100 |
|
Total |
10000 |
BUSINESS DETAILS
|
Line of Business : |
Manufacturers
of Vaccine |
GENERAL
INFORMATION
|
|
|
|
Banking Relations : |
Unknown |
CAPITAL STRUCTURE
Authorised
Capital :
|
No.
of Shares |
Type |
Value |
Amount |
|
50000 |
Equity
Shares |
Rs.10/- each |
Rs.0.500 millions |
Issued,
Subscribed & Paid-up Capital :
|
No.
of Shares |
Type |
Value |
Amount |
|
10000 |
Equity
shares |
Rs.10/- each |
Rs.100 millions |
FINANCIAL DATA
[all figures are in Rupees
Millions]
Financials :
As the
subject is a new company, no financials are available.
Management
remained non-cooperative during current investigation.
LOCAL AGENCY
FURTHER INFORMATION
Website
Details :
At a time when India is showing great progress as a
destination for vaccine Research and development, Manufacturing etc., subject
is all set to make the giant leap into the big league of vaccine manufacturing.
Started 10 years ago under the name Green Signal, They
have been very successful in all their business deals in India. They have been
in Pharma field for the last five years and now they have diversified into
manufacturing vaccine. With a aim to go global, subject has many on-going joint
venture projects with many Government and Private Manufacturers of the World.
Besides manufacturing, a Research and Development
Laboratory for carrying out clinical trials and pilot projects in seed
development, vaccine manufacturing etc., is being set-up at the TICEL Park,
Chennai, Tamil Nadu, India.
The company aims at “Quality Health care for all “ and
to make available the much needed immunologicals at a lesser cost to the masses
in India .For this, high-end equipments imported from various parts of the
world are used in the production. Manufacturing and quality control on par with
international Standards. In India, subject has judicial developmental
partnerships, new products in pipeline, economical pricing and successful
marketing strategies for vaccine field.
Their Objectives
To provide
more and better bacterial and viral vaccines and other biological preparations
for the society and to prevent and eradicate diseases for the various welfare
of people.
To
implement scientific administration and give priority to manufacture high
quality products and ensure a leading position in catering to the large masses
below the poverty line around the world.
To follow
the modern developments in the biological field and laterally
develop cutting-edge technology products so as to make significant
contributions to people’s health and welfare.
Products
Vaccines
Ø
Bacterial
Ø BCG
Ø Diphtheria Toxoid
Ø Acellular pertussis Vaccine
Ø Tetanus Toxoid
Ø DPT
Ø DT
Viral
Ø
Measles
Ø
Rabies
Ø
Rubella
CMT REPORT [Corruption, Money
laundering & Terrorism]
The
Public Notice information has been collected from various sources including but
not limited to: The Courts, India Prisons Service, Interpol, etc.
1] INFORMATION
ON DESIGNATED PARTY
No records exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating money-laundering,
anti-corruption or bribery or international economic or anti-terrorism sanction
laws or whose assets were seized, blocked, frozen or ordered forfeited for
violation of money laundering or international anti-terrorism laws.
2] Court
Declaration :
No records exist to suggest that subject is or was the subject of any
formal or informal allegations, prosecutions or other official proceeding for
making any prohibited payments or other improper payments to government
officials for engaging in prohibited transactions or with designated parties.
3] Asset
Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record
on Financial Crime :
Charges or conviction registered
against subject: None
5] Records
on Violation of Anti-Corruption Laws :
Charges or investigation registered
against subject: None
6] Records
on Int’l Anti-Money Laundering Laws/Standards :
Charges or investigation registered
against subject: None
7] Criminal
Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation
with Government :
No record
exists to suggest that any director or indirect owners, controlling shareholders,
director, officer or employee of the company is a government official or a
family member or close business associate of a Government official.
9] Compensation
Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA
INFORM as part of its Due Diligence do provide comments on Corporate Governance
to identify management and governance. These factors often have been predictive
and in some cases have created vulnerabilities to credit deterioration.
Our
Governance Assessment focuses principally on the interactions between a company’s
management, its Board of Directors, Shareholders and other financial
stakeholders.
CONTRAVENTION
Subject
is not known to have contravened any existing local laws, regulations or
policies that prohibit, restrict or otherwise affect the terms and conditions
that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US
Dollar |
1 |
Rs.44.24 |
|
UK
Pound |
1 |
Rs.86.95 |
|
Euro |
1 |
Rs.57.33 |
SCORE &
RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
3 |
|
PAID-UP CAPITAL |
1~10 |
2 |
|
OPERATING SCALE |
1~10 |
-- |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
-- |
|
--PROFITABILIRY |
1~10 |
-- |
|
--LIQUIDITY |
1~10 |
3 |
|
--LEVERAGE |
1~10 |
-- |
|
--RESERVES |
1~10 |
-- |
|
--CREDIT LINES |
1~10 |
3 |
|
--MARGINS |
-5~5 |
-- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
NO |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
NO |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
11 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit
history (10%) Market
trend (10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial
base with the strongest capability for timely payment of interest and
principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No
caution needed for credit transaction. It has above average (strong) capability
for payment of interest and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are
regarded healthy. General unfavourable factors will not cause fatal effect.
Satisfactory capability for payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal.
Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors
carry similar weight in credit consideration. Capability to overcome
financial difficulties seems comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of
interest and principal sums in default or expected to be in default upon
maturity |
Limited with full security |
|
<10 |
C |
Absolute credit risk exists. Caution
needed to be exercised |
Credit not recommended |
|
NR |
In view of the lack of information, we
have no basis upon which to recommend credit dealings |
No Rating |
|